Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Top Cited Papers
- 19 February 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 10 (3), 223-232
- https://doi.org/10.1016/s1470-2045(09)70003-8
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Hypomethylation and apoptosis in 5-azacytidine–treated myeloid cellsExperimental Hematology, 2008
- Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypesCancer, 2007
- Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid NeoplasmsCancer Research, 2006
- Myelodysplastic SyndromesHematology, 2004
- A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromesThe Hematology Journal, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly?Annals of Hematology, 1993
- The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup studyAnnals of Hematology, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958